ATNM

Actinium Pharmaceuticals, Inc. develops targeted radiotherapies aimed at improving patient outcomes in cancer treatment. Its lead product candidate, ATNM-400, utilizes Actinium-225 to target metastatic castration-resistant prostate cancer, non-small cell lung cancer, and breast cancer, demonstrating efficacy in preclinical studies. The company also advances Actimab-A, a therapeutic for acute myeloid leukemia, and Iomab-ACT, designed to enhance access to cell and gene therapies. Actinium operates primarily in the oncology sector, focusing on both hematological and solid tumor indications.